T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel

Stock Information for Limbach Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Limbach Holdings Inc.

T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease
T2 Biosystems Announces First Quarter 2024 Financial Results
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.